Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Marina C. Garassino, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Giovanna Speranza, Manuel Domine, Maximilian J. Hochmair, Steven Powell, Susanna Yee-Shan Cheng, Helge G. Bischoff, Nir Peled, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Ziwen Wei, Thomas Burke, M. Catherine Pietanza, Delvys Rodríguez-Abreu

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.'. Together they form a unique fingerprint.

Medicine & Life Sciences